KRAS and neoplasm: Luteolin and its derivative apigenin are reported to significantly suppress the expression of PD-L1 induced by IFN-γ, leading to the better anti-tumor activity of KRAS-mutant lung cancer, and a synergistic effect combined with PD-1 ICIs [98].